Compare ESCA & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | GANX |
|---|---|---|
| Founded | 1922 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.7M | 159.2M |
| IPO Year | N/A | 2021 |
| Metric | ESCA | GANX |
|---|---|---|
| Price | $14.61 | $1.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 17.6K | ★ 865.6K |
| Earning Date | 02-25-2026 | 03-26-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $241,540,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.00 | N/A |
| P/E Ratio | $15.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.41 | $1.41 |
| 52 Week High | $16.99 | $4.34 |
| Indicator | ESCA | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 64.77 | 32.04 |
| Support Level | $14.50 | $1.61 |
| Resistance Level | $14.96 | $2.07 |
| Average True Range (ATR) | 0.37 | 0.15 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 87.39 | 5.66 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.